Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Schizophr Res ; 267: 451-461, 2024 May.
Article in English | MEDLINE | ID: mdl-38643726

ABSTRACT

The methylazoxymethanol acetate (MAM) rodent model is used to study aspects of schizophrenia. However, numerous studies that have employed this model have used only males, resulting in a dearth of knowledge on sex differences in brain function and behaviour. The purpose of this study was to determine whether differences exist between male and female MAM rats in neuronal oscillatory function within and between the prefrontal cortex (PFC), ventral hippocampus (vHIP) and thalamus, behaviour, and in proteins linked to schizophrenia neuropathology. We showed that female MAM animals exhibited region-specific alterations in theta power, elevated low and high gamma power in all regions, and elevated PFC-thalamus high gamma coherence. Male MAM rats had elevated beta and low gamma power in PFC, and elevated vHIP-thalamus coherence. MAM females displayed impaired reversal learning whereas MAM males showed impairments in spatial memory. Glycogen synthase kinase-3 (GSK-3) was altered in the thalamus, with female MAM rats displaying elevated GSK-3α phosphorylation. Male MAM rats showed higher expression and phosphorylation GSK-3α, and higher expression of GSK-ß. Sex-specific changes in phosphorylated Tau levels were observed in a region-specific manner. These findings demonstrate there are notable sex differences in behaviour, oscillatory network function, and GSK-3 signaling in MAM rats, thus highlighting the importance of inclusion of both sexes when using this model to study schizophrenia.


Subject(s)
Disease Models, Animal , Methylazoxymethanol Acetate , Schizophrenia , Sex Characteristics , Animals , Methylazoxymethanol Acetate/pharmacology , Schizophrenia/physiopathology , Schizophrenia/chemically induced , Schizophrenia/metabolism , Female , Male , Rats , Prefrontal Cortex/drug effects , Prefrontal Cortex/physiopathology , Prefrontal Cortex/metabolism , Glycogen Synthase Kinase 3/metabolism , Hippocampus/drug effects , Hippocampus/metabolism , Hippocampus/physiopathology , Thalamus/drug effects , Thalamus/physiopathology , Thalamus/metabolism , Phosphorylation/drug effects , tau Proteins/metabolism , Neurons/drug effects , Neurons/metabolism , Neurons/physiology , Neurons/pathology , Rats, Sprague-Dawley
2.
J Psychopharmacol ; 34(7): 759-770, 2020 07.
Article in English | MEDLINE | ID: mdl-32248751

ABSTRACT

BACKGROUND: Mitragynine is the major alkaloid of Mitragyna speciosa (kratom) with potential as a therapeutic in pain management and in depression. There has been debate over the potential side effects of the drug including addiction risk and cognitive decline. AIMS: To evaluate the effects of mitragynine on neurophysiological systems function in the prefrontal cortex (PFC), cingulate cortex (Cg), orbitofrontal cortex, nucleus accumbens (NAc), hippocampus (HIP), thalamus (THAL), basolateral amygdala (BLA) and ventral tegmental area of rats. METHODS: Local field potential recordings were taken from animals at baseline and for 45 min following mitragynine administration (10 mg/kg, intraperitoneally). Drug-induced changes in spectral power and coherence between regions at specific frequencies were evaluated. Mitragynine-induced changes in c-fos expression were also analyzed. RESULTS: Mitragynine increased delta power and reduced theta power in all three cortical regions that were accompanied by increased c-fos expression. A transient suppression of gamma power in PFC and Cg was also evident. There were no effects of mitragynine on spectral power in any of the other regions. Mitragynine induced a widespread reduction in theta coherence (7-9 Hz) that involved disruptions in cortical and NAc connectivity with the BLA, HIP and THAL. CONCLUSIONS: These findings show that mitragynine induces frequency-specific changes in cortical neural oscillatory activity that could potentially impact cognitive functioning. However, the absence of drug effects within regions of the mesolimbic pathway may suggest either a lack of addiction potential, or an underlying mechanism of addiction that is distinct from other opioid analgesic agents.


Subject(s)
Brain/drug effects , Electrophysiological Phenomena , Mitragyna/chemistry , Secologanin Tryptamine Alkaloids/pharmacology , Animals , Brain/metabolism , Male , Proto-Oncogene Proteins c-fos/genetics , Rats , Rats, Wistar , Secologanin Tryptamine Alkaloids/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL
...